Acinetobacter Baumannii Secreted Protease CpaA Inhibits Factor XII-Mediated Bradykinin Generation and Neutrophil Activation
Circulation Research · 2025
DOI: 10.1161/circresaha.124.324764 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation Research, 2025. Verfasst von Kris M Blair und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology (K.M.B., B.A., C.G., M.X.O., M.S.), University of Michigan Medical School, Ann Arbor. Hauptthemen laut MEDLINE: Bradykinin, Neutrophil Activation, Acinetobacter baumannii, Factor XII. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
BACKGROUND: FXII (coagulation factor XII) is best known for its roles in the contact and kallikrein-kinin pathways. FXII is converted to FXIIa (activated factor XII) by PKa (plasma kallikrein) or its unique ability to autoactivate on bacterial or other biologic surfaces. In vivo, FXIIa initiates the intrinsic coagulation pathway and promotes inflammation by reciprocal activation of prekallikrein, which cleaves HK (high-molecular-weight kininogen) to liberate bradykinin. CpaA (coagulation targeting metallo-endopeptidase of A baumannii ) is a secreted metalloprotease identified in a human clinical isolate of Acinetobacter baumannii that cleaves FXII at O-linked glycosylated sites, inhibiting contact activation. While CpaA facilitates a modest in vivo fitness advantage in mice, the role of CpaA in human infection remains unclear. As such, the objectives of this study were to characterize the structural details of the interaction between CpaA, FXII, and the KKS (kallikrein-kinin system) and to determine the downstream consequences on thromboinflammatory responses. METHODS: The effect of purified CpaA on the coagulant activity of FXII and the generation of bradykinin was characterized. Neutrophil signaling, flow cytometry, and functional assays were performed to define how CpaA-mediated cleavage of FXII affects innate immune functions. Bacterial killing by human neutrophils was performed with wild-type and mutant A baumannii strains lacking CpaA. RESULTS: We found that CpaA cleaves both FXII zymogen and FXIIa but not beta Factor XII. However, cleavage of FXIIa by CpaA does not significantly inhibit its clotting activity, demonstrating that CpaA does not inactivate FXIIa, but rather prevents activation of zymogen FXII. CpaA also cleaves HK, resulting in reduced kallikrein activation and bradykinin generation. We previously identified that zymogen FXII interacts with the urokinase receptor on neutrophils and upregulates neutrophil activation. Here, we demonstrate that CpaA cleaves neutrophil FXII, resulting in reduced Akt2 phosphorylation, chemotaxis, oxidative burst, and neutrophil extracellular trap formation. Importantly, CpaA decreases the human neutrophil killing efficiency of A baumannii in culture. CONCLUSIONS: These data identify a role for FXII in responding to bacterial infection and suggest that by inhibiting the contact and kallikrein-kinin pathways and impairing neutrophil activation, CpaA may blunt the innate immune response and help prevent the elimination of A baumannii from the human host.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology (K.M.B., B.A., C.G., M.X.O., M.S.), University of Michigan Medical School, Ann Arbor.
- Presently at Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Louisiana State University School of Veterinary Medicine, Baton Rouge (K.M.B.).
- Hematology and Oncology Division, Department of Medicine, Case Western Reserve University (CWRU) School of Medicine, Cleveland, OH (D.J.B., K.L.B., E.X.S.).
- Division of Cardiovascular Medicine, Department of Internal Medicine (M.W., D.A.L.), University of Michigan Medical School, Ann Arbor.
- Department of Pathobiological Sciences, Louisiana State University School of Veterinary Medicine, Baton Rouge (B.A.).
- Hematology and Oncology Division, Department of Medicine, University Hospitals Cleveland Medical Center, OH (E.G.).
ORCID-Profile: Kris M Blair, Dillon J Bohinc, Kara L Bane, Basel Abuaita, Colby Gura, Eduarda Grinsztejn, Brigid M Wilson, Robert A Bonomo, Mary X O'Riordan, Daniel A Lawrence, Evi X Stavrou, Maria Sandkvist
Förderung
- NHLBI NIH HHS
- NIDDK NIH HHS
- NIAID NIH HHS
- BLRD VA
- NCI NIH HHS
Zitieren
APA
Blair, K. M., Bohinc, D. J., Bane, K. L., Warnock, M., Abuaita, B., Gura, C., Grinsztejn, E., Marshall, S. H., Wilson, B. M., Bonomo, R. A., Tambralli, A., Knight, J. S., O'Riordan, M. X., Lawrence, D. A., Stavrou, E. X., & Sandkvist, M. (2025). Acinetobacter Baumannii Secreted Protease CpaA Inhibits Factor XII-Mediated Bradykinin Generation and Neutrophil Activation. Circulation Research. https://doi.org/10.1161/circresaha.124.324764
Vancouver
Blair KM, Bohinc DJ, Bane KL, Warnock M, Abuaita B, Gura C, et al. Acinetobacter Baumannii Secreted Protease CpaA Inhibits Factor XII-Mediated Bradykinin Generation and Neutrophil Activation. Circulation Research. 2025. doi:10.1161/circresaha.124.324764
BibTeX
@article{Blair2025,
author = {Blair, Kris M and Bohinc, Dillon J and Bane, Kara L and Warnock, Mark and Abuaita, Basel and Gura, Colby and Grinsztejn, Eduarda and Marshall, Steven H and Wilson, Brigid M and Bonomo, Robert A and Tambralli, Ajay and Knight, Jason S and O'Riordan, Mary X and Lawrence, Daniel A and Stavrou, Evi X and Sandkvist, Maria},
title = {Acinetobacter Baumannii Secreted Protease CpaA Inhibits Factor XII-Mediated Bradykinin Generation and Neutrophil Activation},
journal = {Circulation Research},
year = {2025},
doi = {10.1161/circresaha.124.324764}
}
EUVIMED